Xeris Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

xerispharma.com

Stage

IPO | IPO

Total Raised

$153.58M

Date of IPO

6/21/2018

Market Cap

0.24B

Stock Price

1.79

About Xeris Pharmaceuticals

Xeris is a specialty biopharmaceutical company focused on developing improved and differentiated injectable therapeutics for multiple indications in diabetes, epilepsy, and immunology. The company's XeriSol and XeriJect formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using auto-injectors, multi-dose pens, and pumps.

Xeris Pharmaceuticals Headquarter Location

180 N LaSalle St Suite 1800

Chicago, Illinois, 60601,

United States

844-445-5704

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Xeris Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xeris Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Xeris Pharmaceuticals Patents

Xeris Pharmaceuticals has filed 30 patents.

The 3 most popular patent topics include:

  • Amines
  • Diabetes
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/6/2015

9/28/2021

Medical equipment, Drug delivery devices, Dosage forms, Fluid dynamics, Pharmacokinetics

Grant

Application Date

8/6/2015

Grant Date

9/28/2021

Title

Related Topics

Medical equipment, Drug delivery devices, Dosage forms, Fluid dynamics, Pharmacokinetics

Status

Grant

Latest Xeris Pharmaceuticals News

Xeris Pharmaceuticals Q1 2022 Earnings Preview

May 10, 2022

Xeris Pharmaceuticals (NASDAQ: XERS ) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.24 (+20.0% Y/Y) and the consensus Revenue Estimate is $23.39M (+190.6% Y/Y). Over the last 2 years, XERS has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Xeris Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Xeris Pharmaceuticals Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.